Scholar Rock's ISEMBYLD Wins FDA Approval As First Muscle-Targeted Therapy For SMA

Scholar Rock announced FDA approval of ISEMBYLD (apitegromab-mstn) to treat spinal muscular atrophy in adults and children aged two years and older who are receiving survival motor neuron 2 therapy. The approval creates a new commercial opportunity for Scholar Rock in SMA and materially de-risks the company’s lead product.